loading
Schlusskurs vom Vortag:
$7.17
Offen:
$7.26
24-Stunden-Volumen:
1.03M
Relative Volume:
0.56
Marktkapitalisierung:
$2.35B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-11.00
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
+2.39%
1M Leistung:
+4.39%
6M Leistung:
-11.30%
1J Leistung:
+12.03%
1-Tages-Spanne:
Value
$7.26
$7.495
1-Wochen-Bereich:
Value
$7.07
$7.51
52-Wochen-Spanne:
Value
$6.29
$9.475

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name
Firmenname
Amneal Pharmaceuticals Inc
Name
Telefon
908-947-3120
Name
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Name
Mitarbeiter
5,210
Name
Twitter
@amnealpharma
Name
Nächster Verdiensttermin
2025-05-02
Name
Neueste SEC-Einreichungen
Name
AMRX's Discussions on Twitter

Vergleichen Sie AMRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
AMRX
Amneal Pharmaceuticals Inc
7.485 2.29B 2.68B -184.45M 229.23M -0.6805
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.07 50.98B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
169.71 74.41B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.935 4.03M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.95 46.23B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.54 20.10B 16.54B -1.64B 749.00M -1.45

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-24 Hochstufung JP Morgan Neutral → Overweight
2024-09-06 Hochstufung JP Morgan Underweight → Neutral
2021-04-07 Fortgesetzt RBC Capital Mkts Sector Perform
2021-03-08 Hochstufung Goldman Sell → Buy
2020-12-14 Hochstufung Barclays Equal Weight → Overweight
2020-12-14 Hochstufung Guggenheim Neutral → Buy
2020-07-27 Eingeleitet Goldman Sell
2020-05-12 Hochstufung Guggenheim Sell → Neutral
2019-12-12 Herabstufung Raymond James Outperform → Mkt Perform
2019-11-12 Herabstufung JP Morgan Neutral → Underweight
2019-11-07 Herabstufung SVB Leerink Outperform → Mkt Perform
2019-07-22 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-07-11 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2019-07-08 Hochstufung Piper Jaffray Neutral → Overweight
2019-06-11 Eingeleitet Barclays Equal Weight
2019-05-21 Hochstufung Raymond James Mkt Perform → Strong Buy
2019-03-20 Eingeleitet SunTrust Buy
2019-03-08 Herabstufung SVB Leerink Outperform → Mkt Perform
2018-12-14 Herabstufung Morgan Stanley Overweight → Equal-Weight
2018-10-16 Herabstufung SunTrust Buy → Hold
2018-08-13 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2018-07-23 Eingeleitet Morgan Stanley Overweight
2018-06-22 Eingeleitet B. Riley FBR, Inc. Buy
Alle ansehen

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

pulisher
11:39 AM

Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN

11:39 AM
pulisher
04:45 AM

AMRX Stock Coverage Initiated with Buy Rating by Goldman Sachs | AMRX Stock News - GuruFocus

04:45 AM
pulisher
04:30 AM

Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating - Investing.com

04:30 AM
pulisher
Jun 05, 2025

Amneal Pharmaceuticals at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

Global Antidote Market to Cross the USD 4 Billion Mark by 2032 | DelveInsight - GlobeNewswire Inc.

Jun 05, 2025
pulisher
Jun 05, 2025

Amneal Pharmaceuticals Initiates Nationwide Recall of Contaminated Sulfamethoxazole/Trimethoprim Tablets - Insider Monkey

Jun 05, 2025
pulisher
Jun 04, 2025

Amneal Pharmaceuticals (AMRX) Recalls Antibiotic Due to Contamination - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Amneal announces recall of oral antibiotic (AMRX:NASDAQ) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Amneal Recalls Three Lots of Urinary Tract Infection Tablets - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Amneal Pharmaceuticals (AMRX) Recalls Contaminated Tablets Due to Quality Concerns | AMRX Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade - sharewise

Jun 04, 2025
pulisher
Jun 04, 2025

Amneal Recalls Oral Antibiotic Over Contamination Issue - Medical Professionals Reference

Jun 04, 2025
pulisher
Jun 01, 2025

Amneal Pharmaceutical LLC Issues a Nationwide Recall of Sulfamethoxazole / Trimethoprim Tablets, USP, 400 mg/80 mg Only, Due to Microbial Contamination - US Recall News

Jun 01, 2025
pulisher
May 29, 2025

Amneal to Participate at Upcoming Investor Conferences in June - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Amneal CEO and CFO Set for Exclusive Presentations at Two Major Healthcare Investor Conferences - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Bank of America Corp DE Has $4.41 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 29, 2025
pulisher
May 28, 2025

FDA approves Amneal’s DHE migraine/cluster headache autoinjector - MSN

May 28, 2025
pulisher
May 28, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $716,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 28, 2025
pulisher
May 27, 2025

Pharyngitis Treatment Market with Antibiotics and Home - openPR.com

May 27, 2025
pulisher
May 26, 2025

3 Reasons Growth Investors Will Love Amneal (AMRX) - Yahoo Finance

May 26, 2025
pulisher
May 26, 2025

Deutsche Bank AG Has $1.06 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 26, 2025
pulisher
May 22, 2025

Hydroxychloroquine Market to Witness Remarkable Growth with - openPR.com

May 22, 2025
pulisher
May 22, 2025

Insider Sell: Nikita Shah Sells Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsight - PR Newswire

May 21, 2025
pulisher
May 20, 2025

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by BNP Paribas Financial Markets - Defense World

May 20, 2025
pulisher
May 19, 2025

Ameriprise Financial Inc. Sells 49,121 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 19, 2025
pulisher
May 16, 2025

Amneal gets U.S. FDA nod for Brekiya as a migraine treatment - MSN

May 16, 2025
pulisher
May 16, 2025

US FDA approves Amneal's self-administered migraine treatment - Reuters

May 16, 2025
pulisher
May 16, 2025

AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress - Yahoo Finance

May 16, 2025
pulisher
May 16, 2025

Amneal Gets FDA Nod For Self-Administrable Migraine Injection - MSN

May 16, 2025
pulisher
May 16, 2025

The Manufacturers Life Insurance Company Has $689,000 Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 16, 2025
pulisher
May 16, 2025

Amneal gets FDA approval for Brekiya to treat migraine and cluster headaches - World Pharmaceutical Frontiers

May 16, 2025
pulisher
May 16, 2025

Amneal’s Brekiya autoinjector approved by FDA for migraines - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

Northern Trust Corp Purchases 156,699 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 16, 2025
pulisher
May 15, 2025

Amneal’s Brekiya autoinjector approved by FDA for migraines By Investing.com - Investing.com South Africa

May 15, 2025
pulisher
May 15, 2025

Amneal Gets FDA Nod For Self-Administrable Migraine Injection By Stocktwits - Investing.com India

May 15, 2025
pulisher
May 15, 2025

FDA Approves Amneal's (AMRX) Brekiya Autoinjector for Migraine R - GuruFocus

May 15, 2025
pulisher
May 15, 2025

US FDA approves Amneal’s self-administered migraine treatment - 1470 & 100.3 WMBD

May 15, 2025
pulisher
May 15, 2025

FDA Greenlights Amneal's (AMRX) Innovative Migraine Treatment | AMRX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Amneal Pharmaceuticals' Brekiya Approved by FDA - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Amneal rises after US FDA greenlights self-administered migraine treatment - TradingView

May 15, 2025
pulisher
May 15, 2025

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults - The Manila Times

May 15, 2025
pulisher
May 15, 2025

US FDA approves Amneal's migraine treatment - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Amneal Receives U.S. FDA Approval for Brekiya® - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

Breakthrough: First At-Home Injectable Migraine Treatment Gets FDA Green LightWhat Makes It Different - Stock Titan

May 15, 2025
pulisher
May 15, 2025

This Insider Has Just Sold Shares In Amneal Pharmaceuticals - simplywall.st

May 15, 2025
pulisher
May 15, 2025

Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Lowered by StockNews.com - Defense World

May 15, 2025
pulisher
May 13, 2025

Director John Kiely Sells 50,000 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

May 13, 2025
pulisher
May 12, 2025

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing - insights.citeline.com

May 12, 2025
pulisher
May 12, 2025

Key Trends Shaping the Future of Filgrastim Biosimilars Market: Amneal Pharmaceuticals' Fylnetra Marks A Ne... - WhaTech

May 12, 2025
pulisher
May 10, 2025

Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock? - MSN

May 10, 2025

Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$8.595
price up icon 1.77%
$126.55
price up icon 0.95%
drug_manufacturers_specialty_generic RDY
$15.46
price down icon 0.45%
drug_manufacturers_specialty_generic HCM
$15.12
price down icon 0.39%
$324.00
price down icon 0.79%
$17.51
price up icon 1.54%
Kapitalisierung:     |  Volumen (24h):